Evidence map›Paper›PMID 25137036›Full record

Trial reportMetabolic syndrome and related disorders2014

Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion.

Miriam Méndez-del Villar, Manuel González-Ortiz, Esperanza Martínez-Abundis, Karina G Pérez-Rubio, Roberto Lizárraga-Valdez

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Metabolic syndrome and related disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 11 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 11 syntheses or guidelines pooled it, 240 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Resveratrol for adults with type 2 diabetes mellitus.The Cochrane database of systematic reviews · 2020
    Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Phytocompounds That Target White Adipose Tissue for Weight Loss: A Review Spanning From Ucp1 Induction in Rodents to Human Clinical Trials.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2026
    Review
  18. Effect of Celery Seed (Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  19. Review
  20. Review

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Miriam Méndez-del VillarInstitute of Experimental and Clinical Therapeutics, Department of Physiology, Health Science University Center, University of Guadalajara , Guadalajara, Mexico .
Manuel González-Ortiz
Esperanza Martínez-Abundis
Karina G Pérez-Rubio
Roberto Lizárraga-Valdez
Universidad de Guadalajara · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimThis study evaluated the effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion.

methodsA randomized, double-blind, placebo-controlled clinical trial was carried out in 24 patients with diagnosis of metabolic syndrome in accordance with the International Diabetes Federation criteria. Glucose and insulin levels were measured after a 75-gram dextrose load. Triglycerides and high-density lipoprotein cholesterol concentrations at baseline were also evaluated. Twelve patients received trans-resveratrol (500 mg) three times per day before meals for 90 days. The remaining 12 patients received placebo at the same dose. The area under the curve (AUC) values of glucose and insulin, total insulin secretion, first-phase of insulin secretion, and insulin sensitivity were calculated.

resultsAfter resveratrol administration, there were significant differences in total weight (94.4±13.2 vs. 90.5±12.3 kg, P=0.007), body mass index (BMI) (35.6±3.2 vs. 34.3±3.0 kg/m(2), P=0.006), fat mass (41.2±7.9 vs. 38.8±6.0 kg, P=0.001), and waist circumference (WC) (109±9 vs. 105±10 cm, P=0.004). There were also significant differences in AUC of insulin (48,418±22,707 vs. 26,473±8,273 pmol/L, P=0.003) and insulinogenic index (0.48±0.22 vs. 0.28±0.08, P=0.004).

conclusionsAdministration of resveratrol significantly decreases weight, BMI, fat mass, WC, AUC of insulin, and total insulin secretion.

Indexed as

Insulin ResistanceAdiposityAdultArea Under CurveBiomarkersBlood GlucoseBody Mass IndexCholesterol, HDLDouble-Blind MethodFemaleHumansHyperinsulinismInsulinMaleMetabolic SyndromeMexicoBiomarkersBlood GlucoseCholesterol, HDLInsulinResveratrolStilbenesTriglycerides

Identifiers

PMID25137036
OpenAlexW2075638146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.